Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Novo Nordisk lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S.

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings, but cut its guidance ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

The company founded in 1963 - which influenced hundreds of millions of people in the US and around the world - has filed for ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

U.S. trade policy has also heightened investor concerns over the potential impact to Novo Nordisk's key market. U.S. President Trump has threatened to unveil tariffs on pharmaceutical products in the ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...